Biotech Co.* |
Agbiotech Partner (Country; Symbol) |
Type/Product Area |
Terms/Details (Date) |
| | |||
Agilent Technologies Inc. (NYSE:A) and Rosetta Biosoftware (unit of Rosetta Inpharmatics Inc., a subsidiary of Merck & Co. Inc.) |
Pioneer Hi-Bred International Inc. (subsidiary of DuPont) |
Agreement in which Pioneer Hi-Bred will analyze Agilent's microarray data using the Rosetta Resolver system |
Financial terms were not disclosed; Pioneer is looking to gain a better understanding of genes responsible for triggering and controlling complex plant processes (1/13) |
|
|
||
Agrinomics LLC (joint venture between Exelixis Inc. and Bayer CropScience AG) |
Renessen LLC (joint venture between Monsanto Co. and Cargill Inc.) |
Collaboration to enhance the oil content in commercially valuable seed oil crops |
The collaboration combines Agrinomics' high-throughput gene screening and seed trait identification with Renessen's expertise in trait crop development and commercialization, with the goal of accelerating the development of crops with improved seed composition traits (12/19) |
|
|
||
Athenix Corp.* |
Mertec LLC* |
Collaboration in which the companies plan to bring developed traits from Athenix to the market in soybean varieties developed by Mertec |
Mertec would market the co-developed soybean varieties (5/29) |
|
|||
Bioenvision Inc. |
Dechra Pharmaceuticals plc (UK; LSE:DPH) |
Sublicensing agreement giving Dechra U.S. and Canadian marketing and development rights to trilostane for animal health applications |
Bioenvision would receive an additional $750,000 upon submission of a new animal drug application to the FDA and $3M upon approval, as well as royalties (5/27) |
|
|||
BioResources International Inc.* |
Unigen Pharmaceutical Inc.* |
Collaborative plant collection agreement |
BioResources will source, collect and identify plants with ethnomedicinal use that are indigenous to Ghana, as well as provide Unigen with historical usage and taxonomic data specific to each plant (2/13) |
|
|
||
Cellectis SA* |
BASF Plant Science GmbH (Germany; unit of BASF AG; Germany; NYSE:BF; LSE:BFA) |
Collaboration to evaluate the possible use of Cellectis' Meganuclease I-Scel technology for the deletion/excision of nucleotide sequences, such as marker genes, in plants for agricultural and nutritional applications |
Financial terms were not disclosed (5/28**) |
|
|||
Cellectis SA* |
Limagrain Group* (France) |
Agreement that includes an option for a nonexclusive, worldwide license to use Cellectis' Meganuclease Recombination System technology |
Limagrain is a seed business; financial terms were not disclosed (4/9) |
|
|
||
Cellectis SA* |
Pioneer Hi-Bred International Inc. (subsidiary of DuPont) |
Expanded agreement to introduce traits into maize |
Pioneer Hi-Bred researchers will assess the Meganuclease Recombination System from Cellectis for use in trait development (3/18) |
|
|||
CompleGen Inc.* |
DuPont Crop Protection (unit of DuPont) |
Agreement in which CompleGen delivered targeted cell-based assays for high- throughput compound screening to DuPont |
DuPont will use the assays to discover compounds active on agricultural pathogens (3/28) |
|
|||
Devgen NV* |
FMC Corp. (NYSE:FMC) |
Agreement to extend their collaboration to April 2006 |
The four-year-old agreement has identified several new insecticide targets, genetically validated them and built them into high-throughput screening assays (4/23) |
|
|||
Devgen NV* |
Sumitomo Chemical Company Ltd. (Japan; FSE:SMMG) |
Three-year research collaboration to develop insecticides |
Devgen will select and further validate insecticidal targets and format high-throughput assays to screen small-molecule compounds designed by Sumitomo; Devgen will deliver insect active hits, which Sumitomo will develop further into marketed products; Devgen will receive an undisclosed upfront payment and research funding and is eligible for milestones and royalties (5/19) |
|
|||
Diversa Corp. |
DuPont |
Six-year alliance to discover and develop biocatalysts for the production of fuel ethanol, 1,3 propanediol and other chemicals from renewable resources such as corn and biomass |
DuPont will receive $19M in matching funds from the U.S. Department of Energy over four years; Diversa will collaborate with DuPont on the biorefinery grant and will receive research funding, as well as milestone payments and royalties (5/1) |
|
|||
Durect Corp. |
Thorn BioScience LLC* |
Expanded agreement for the development and commercialization of veterinary products for reproductive indications using Durect's Saber delivery system |
Durect granted Thorn an exclusive, worldwide license to use the Saber delivery system to provide a sustained-release therapy for reproductive indications for specified animal species (11/14) |
|
|||
Genetic |
Inguran LP* |
Agreement granting a license to Genetic Technologies' noncoding patents to Inguran |
The license will permit Inguran to provide various genetic testing services for genetic markers of interest, paternity and disease susceptibility on livestock in the U.S., Colombia and Brazil (6/19) |
|
|||
GTC Biotherapeutics |
Trans Ova Genetics Inc.* |
Agreement enabling Trans Ova to develop the production of veterinary antibodies, initially for three diseases in cattle |
GTC granted Trans Ova an exclusive license to develop and maintain a production herd for the antibodies, along with downstream processing rights; the companies work to develop the cattle that produce the antibodies in their milk (1/2) |
|
|
||
IGEN International |
Aviagen Inc.* |
Agreement in which Aviagen adopted IGEN's Pathigen salmonella test method for use in surveillance of its poultry breeding stock |
The Pathigen test method uses IGEN's Origen technology for presumptive identification of salmonella; Aviagen purchased several IGEN instruments and will deploy them at each of its North American sites (6/20) |
|
|||
Oxford BioMedica plc (UK; LSE:OXB) |
Intervet Pharma R&D SA (the Netherlands; subsidiary of Akzo Nobel NV) |
Agreement for the development of Oxford BioMedica's TroVax-VET, a veterinary version of TroVax |
The deal includes an option to acquire a number of other veterinary cancer products arising from Oxford BioMedica's antigen discovery program (1/6) |
|
|||
Large Scale Biology Corp. (LSBC) |
Growers Research Group LLC* |
Agreement in which Large Scale will undertake new funded research for Growers Research under a new contract |
The companies reported a previous deal in June related to lysozyme material; this new deal will focus on developing novel anti-microbial products for plant protection purposes through the application of Large Scale's Geneware technology (12/20) |
|
|||
Locus Pharmaceuticals Inc.* |
DuPont Crop Protection (unit of DuPont) |
Research collaboration to develop compounds for agricultural crop protection |
Locus will apply its computational technology to discover and develop small-molecule compounds that have activity against key protein targets identified by DuPont; Locus will obtain exclusive rights to such targets for human therapeutic uses; Locus will receive reimbursement of research costs, as well as undisclosed milestone and royalty payments from DuPont (1/21) |
|
|||
Nabi |
Pharmacia Animal Health (division of Pharmacia Corp.; NYSE:PHA) |
Exclusive, worldwide licensing agreement for whole-cell vaccine technology for Staphylococcus aureus infections in cattle |
Pharmacia Animal Health made an up-front cash payment and will make future cash payments if certain milestones are achieved; it also would pay royalties based on product sales (4/14) |
|
|||
Paradigm |
Monsanto Co. (NYSE:MON) |
Agreement in which Paradigm's genes analyzed and confirmed as hits in its Arabidopsisthaliana GeneFunction Factory platform moved into corn and soybean research |
Paradigm is testing genes with its platform to discover those that can affect commercially relevant traits (5/27) |
|
|||
SomaLogic Inc.* |
Merial Ltd. (UK; joint venture between Merck and Co. Inc. and Aventis SA) |
Collaboration to develop aptamer-based diagnostics for bovine spongiform encephalopathy |
SomaLogic's technology is based on aptamers, single-stranded DNA molecules that bind target molecules; financial terms were not disclosed (1/27) |
|
| |||
Notes: | |||
#This chart contains information on new and revised corporate agreements in agricultural biotechnology, covering the time between 11/27/02 and 6/26/03. | |||
* Private companies are indicated with an asterisk. | |||
** Denotes the date the item ran in BioWorld International. | |||
Unless otherwise indicated, shares are traded on the Nasdaq exchange. | |||
ASX = Australian Stock Exchange; FSE = Frankfurt Stock Exchange; LSE = London Stock Exchange; NYSE = New York Stock Exchange; OTC BB = Over-the-Counter Bulletin Board. | |||
